Stemline Therapeutics Inc (STML) Receives Consensus Rating of “Buy” from Analysts

Shares of Stemline Therapeutics Inc (NASDAQ:STML) have been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $30.00.

STML has been the subject of a number of analyst reports. BidaskClub downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 16th. ValuEngine raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. Finally, HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 10th.

NASDAQ STML traded up $0.04 during trading on Friday, hitting $15.21. The stock had a trading volume of 3,430 shares, compared to its average volume of 192,912. The company has a market cap of $464.63 million, a P/E ratio of -5.16 and a beta of 0.17. Stemline Therapeutics has a twelve month low of $12.35 and a twelve month high of $20.55.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). The business had revenue of $0.50 million during the quarter. On average, sell-side analysts anticipate that Stemline Therapeutics will post -2.78 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of STML. BlueMountain Capital Management LLC purchased a new stake in Stemline Therapeutics during the second quarter worth approximately $137,000. State Board of Administration of Florida Retirement System purchased a new stake in Stemline Therapeutics during the second quarter worth approximately $166,000. Bank of America Corp DE lifted its stake in Stemline Therapeutics by 97.8% during the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 10,159 shares during the last quarter. Algert Global LLC purchased a new stake in Stemline Therapeutics during the second quarter worth approximately $344,000. Finally, Barclays PLC lifted its stake in Stemline Therapeutics by 77.9% during the first quarter. Barclays PLC now owns 23,423 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 10,254 shares during the last quarter. Hedge funds and other institutional investors own 67.17% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Recommended Story: Outstanding Shares

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply